上海市征用占用林地补偿费管理实施办法
作者:法律资料网 时间:2024-05-22 13:44:09 浏览:9139
来源:法律资料网
下载地址: 点击此处下载
上海市征用占用林地补偿费管理实施办法
上海市征用占用林地补偿费管理实施办法
上海市人民政府
上海市政府批转，上海市农林局、市财政局、市物价局制订
为了保护本市郊区值树造林绿化成果，加强对征用、占用林地的管理，根据《中华人民共和国森林法》及其《实施细则》、《国务院办公厅转发林业部等部门关于进一步加强林地保护管理工作请示的通知》（国办发[1992]32号）以及《上海市植树造林绿化管理条例》的规定，制定本办
法。
一、本市郊县（区）范围内各种林地不得任意征用、占用、借用，禁止毁绿建房。因城市基础设施建设确需征用、占用林地的，须经市农林局审核同意，报市人民政府批准，并交纳林木补偿费、林地补偿费、森林植被恢复费和劳动力安置补助费后，方能办理划拨用地手续。其他建设一
般不得征用、占用林地。
二、凡申请征用、占用林地的单位，应提供下列文件：
（一）征用、占用林地申请书；
（二）县（区）级以上计划主管部门按国家基本建设程序批准的项目计划任务书或其他批准文件；
（三）被征用、占用林地平面图和林木等地面附着物调查清册。
需伐除和挖去树木的，还应由原林地、林木所有权或使用权单位提交采伐林木申请书。
三、征用、占用林地补偿费，按如下标准缴纳：
（一）林木补偿费
1、防护林：以造林、培育（肥培管理、病虫防治、护林防火等，下同）全过程的投入加林木增值或按被征用、占用时林地上的林木实际价值计算。暂定造林当年每亩为1000元，以后每增加一年增加500～800元计算。
2、用材林：同防护林。
3、经济林（果园、桑园，下同）、竹林：以造林、培育全过程的投入加增值或按被征用、占用前三年平均亩产值三至五倍计算。暂定投产前每亩按1500～5000元计算，投产后每亩按5000～30000元计算。
4、特种用途林（包括国防林、实验林、母树林、环境保护林、风景林、名胜古迹林、纪念林、自然保护区林和珍贵树种林，下同）：以防护林的林木补偿费二至三倍计算或以被征用、占用时的实际价值计算。暂定造林当年每亩2000～3000元，以后每增加一年增加1000～2400元计算。
5、苗木：以征用、占用当年或前三年平均亩产值计算。暂定一般用材树苗一年生苗木每亩1500～2000元，二年生苗木每亩2500～3000元，三年生以上苗木每亩3500～6000元；珍贵常绿树苗以一般用材树苗的林木补偿费二至五倍计算或双方面议。
6、“四旁”林木：按植树、培育全过程的投入加增值计算。暂定一般用材树植树当年每株5元，以后每增加一年增加3～5元计算；珍贵常绿树以一般用材树的林木补偿费二至五倍计算或双方面议。
林地上林木）苗木以外的青苗附着物、建筑设施等，按有关规定另行计算：
（二）森木植被恢复费
暂定每亩30000元，免交垦复基金。征用、占用林地单位在被征用、占用林地邻近补足林地的，不缴纳森林植被恢复费。
（三）林地补偿费
按照本市征用、占用菜地的标准和规定办理。
（四）劳动力安置补助费
参照《上海市住宅建设征用集体所有土地农业人口安置办法》（市政府第62号令）的规定执行。
四、征用、占用林地砍伐或起出的林木、苗木，归原林木、苗木权属单位或经营者。起出的林木或苗木能移地培育的，应移地培育后重新用于造林绿化。
五、林木、林地补偿费应实行“谁所有（使用），谁收取”的原则。收取的林木、林地补偿费，除原属于个人的林木或附着物、青苗应获得的补偿付给个人外，统一交由享有原林地、林木所有权或使用权的单位。林木、林地补偿费用于重新造林营林，恢复森林植被和发展林业生产，不
得挪作他用。
六、森林植被恢复费由市农林局收取，并开具由市财政局统一监制的行政事业注收费收据。按照预算外资金管理规定，对森林植被恢复费实行财政专户收支两条线管理，并将此款专门用于森林植被的恢复和管护，以确保新林地建设面积与被证用、占用林地面积基本平衡或新林地建设面
积略有增加。
七、经批准征用、占用林地的划拨，必须由市或所在县（区）林业主管部门派员监督。
八、未经市农林局同意，任何单位和个人不得擅自批准征用、占用林地。对违反本办法征用、占用林地或以其他方式非法占用林地的，按照有关法律、法规的规定处罚。
九、本办法由市财政局、市物价局、市农林局按各自职责范围负责解释，由市农林局负责实施。
十、本办法规定的补偿费标准不适用园林部门管辖的绿地、林木。
十一、本办法自下发之日起施行。
1998年1月4日
下载地址: 点击此处下载
国务院、中央军委批转国防科工委等部门关于解决三线艰苦地区国防科技工业离休退休人员安置和职工夫妻长期两地分居问题的报告的通知
国务院、中央军委批转国防科工委等部门关于解决三线艰苦地区国防科技工业
离休退休人员安置和职工夫妻长期两地分居问题的报告的通知
国务院、中央军委同意国防科工委、劳动人事部、公安部、商业部、财政部《关于解决
三线艰苦地区国防科技工业离休退休人员安置和职工夫妻长期两地分居问题的报告》，现转
发给你们，望遵照执行。
对三线艰苦地区国防科技工业的离休、退休人员和夫妻长期两地分居的职工，给予适当
照顾和妥善安置，对稳定三线职工队伍，巩固和加强三线建设，具有重要意义。希望国防科
技工业各部门和各省、自治区、直辖市人民政府、国务院有关部委要通力合作，积极创造条
件，有计划、有步骤、分期分批地解决好这个问题。
附：
关于解决三线艰苦地区国防科技工业离休退休人员安置和职工夫妻长期两地分居问题的
报告
（一九八四年二月二十九日）
根据国务院、中央军委领导同志的指示精神，国防科工委组织核、航空、兵器、航天、
电子工业部，船舶工业总公司，并会同全国总工会、国防工会等部门，对三线艰苦地区国防
科技工业企事业单位离休、退休人员的安置和职工夫妻长期两地分居的问题进行了调查研究。
国防科技工业在三线艰苦地区的科技人员、干部和工人，有相当一部分是六十年代初期，响
应党的号召，从一、二线和大中城市到三线地区去的。二十多年来，他们长期工作在深山峡
谷、荒原戈壁，艰苦创业，为改善我国的战略布局，加速国防科技工业的发展，作出了贡献。
现在，一部分同志因年老体弱，或积劳成疾，逐渐到了离休、退休年龄，希望组织上给予妥
善安置。有一部分同志由于夫妻两地分居，特别是家属“农转非”的问题长期得不到解决，
加重了职工的负担，影响了职工队伍的稳定。因此，对三线艰苦地区国防科技工业的职工，
给予适当照顾，并制定解决离休、退休人员安置和夫妻长期两地分居的办法，是当前巩固三
线建设，稳定三线队伍，激励更多的中青年同志去三线艰苦地区工作，亟待解决的重要问题。
经与中央、国务院有关部委研究，提出以下解决办法：
一、关于离休、退休人员的安置问题
（一）三线艰苦地区的离休、退休人员，原则上应就地安置。对就地安置的离休、退休
人员，实行以下办法：
（１）凡在三线艰苦地区三类区（高寒、高原、沙漠戈壁、深山峡谷地区）工作累计满
二十年的职工，退休金标准提高１０％；在一类区（无城镇依托、交通不便的偏僻地区）、
二类区（远离城镇和交通干线的穷困地区）工作累计满二十年的职工，退休金标准提高５％。
但提高后的退休金总额，不得超过本人的原标准工资。
（２）享有艰苦地区事业津贴的职工，事业津贴费可同地区生活补贴费一样，对离休的，
包括在原工资内发给；对退休的，作为计算退休费的基数。
（３）当地政府和所在单位，要帮助他们解决就地安置中的实际困难，关心他们的身体
健康和物质文化生活，并在住房、看病等方面给予妥善解决。
（二）对从一、二线和大中城市到三线艰苦地区工作的职工，按实际情况，分别采取以
下安置办法：
（１）在二、三类区工作的离休、退休干部，和在这类地区工作满二十年的退休工人，
可在所在地区交通、医疗等条件比较方便的中小城市安置。
（２）在三类区工作的离休、退休人员，就地就近安置确有困难的，可到本人、配偶原
籍或配偶、子女工作所在地安置。
（３）有条件的单位，对离休老干部和技术六级以上的退休科技人员，可在比较适宜的
城市，修建居住点，予以安置。
（４）凡作易地安置的，有关省、自治区、直辖市公安机关应凭县级以上组织、人事或
民政部门同意安置的证明，准予落户。其中，要求到北京、上海、天津安置的，按有关规定
从严控制。
二、关于解决职工夫妻长期两地分居的问题
（一）凡从一、二线和大中城市到三线艰苦地区工作的夫妻长期两地分居的职工，本人
享受探亲假，并具备下列条件之一者，可以解决夫妻两地分居问题，家属（指配偶，十五周
岁以下和十五周岁以上但不超过十八周岁在中学读书的子女）是农业户口的，可到职工所在
地区转为城镇户口。
（１）根据一九八○年公安部、粮食部、国家人事局《关于解决部分专业技术干部的农
村家属迁往城镇由国家供应粮食问题的规定》的精神，年满三十五周岁以上的工程师，以及
相当这一职称以上的专业技术干部；
（２）年满四十周岁、工龄满二十年，在三线艰苦地区工作满八年以上的其他干部和工
人；
（３）经部（包括部级总公司）和省、自治区、直辖市以上领导部门批准的在科研、生
产和专业工作上有特殊贡献或授予荣誉称号者。
（二）入户审批权限和手续。凡符合“农转非”条件者，由职工所在单位报省、自治区、
直辖市国防科工办，由国防科工办会同省、自治区、直辖市有关部门审批后，持批准的证明，
向迁入地区公安和粮食部门办理户口和粮食供应手续。此项“农转非”指标，不占公安机关
正常审批的控制比例。
经国家批准多销的粮食，可以相应增加商业部门粮食企业的亏损指标和补贴。
（三）凡符合“农转非”条件而不办理“农转非”的，职工本人除按规定每年享受一次
探亲（指探配偶）假外，其配偶每年可到职工所在单位探亲一次，往返路费由职工所在单位
报销。
（四）对环境特别艰苦、条件很差、无法解决职工夫妻两地分居问题的单位，只要工作
可以离得开，又有单位接收的，经过批准，可以分期分批地将夫妻长期两地分居的职工，调
到其配偶所在地区安排工作。
（五）凡不属于上述解决范围的其他干部和工人，解决夫妻长期两地分居问题，应按照
所在地区有关规定办理。
为了集中而又分期分批解决家属“农转非”的问题，建议在报告批准后，请核、航空、
兵器、航天、电子工业部和船舶工业总公司作出计划，先将今后三年内解决“农转非”的准
确数字上报国务院有关部门。经审批后，由国务院有关部门下达专项指标。
三、上述规定，从一九八四年七月一日起执行；所需费用，从各企事业单位或各部门的
有关经费和利润留成中解决。
以上报告，如无不当，请批转有关部门和省、自治区、直辖市人民政府执行。
Special Review and Approval Procedure for Drug Registration of the State Food and Drug Administration
Special Review and Approval Procedure for Drug Registration of the State Food and Drug Administration
(SFDA Decree No. 21)
The Special Review and Approval Procedure for Drug Registration of the State Food and Drug Administration, adopted at the executive meeting of the State Food and Drug Administration (SFDA) on November 18, 2005, is hereby promulgated and shall go into effect as of the date of promulgation.
Shao Mingli
Commissioner of SFDA
November 18, 2005
Special Review and Approval Procedure for Drug Registration of the State Food and
Drug Administration
Chapter 1 General Provisions
Article 1 This Procedure is formulated for the purpose of effective prevention, timely control and elimination of the hazards of public health emergencies to ensure the health and safety of the public in accordance with the Drug Administration Law of the People’s Republic of China, Law of the People’s Republic of China on the Prevention and Treatment of Infectious Diseases, Regulations for Implementation of the Drug Administration Law of the People’s Republic of China, Regulations on Preparedness for and Response to Emergent Public Health Hazards, and other relevant laws and regulations.
Article 2 The special review and approval procedure for drug registration refers to the procedure and requirements of the State Food and Drug Administration to carry out special review and approval of drugs for handling public heath emergencies under the principle of unified leadership, early involvement, expeditiousness and efficiency, and scientific review and approval, in an effort to approve drugs for the prevention and treatment of public health emergencies as soon as possible under the threat or after the occurrence of public heath emergencies.
Article 3 The State Food and Drug Administration may, according to law, decide to follow the Procedure to conduct special review and approval of drugs for public health emergencies in any of the following circumstances:
(1) Where the President of the People’s Republic of China declares a state of emergency or the State Council decides that certain areas within a province, autonomous region or municipality directly under the Central Government are in a state of emergency;
(2) Where the contingency program for public health emergencies is initiated according to law;
(3) Where the drug reserve department or the health administrative department of the State Council proposes a special review and approval for drugs having existing national drug standard;
(4) Other circumstances applicable to special review and approval.
Article 4 The State Food and Drug Administration is responsible for the review and approval of clinical trials, production and importation of drugs for the prevention and treatment of public health emergencies.
The (food and) drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall, upon entrustment of the State Food and Drug Administration, be responsible for on-site inspection and sampling of the pilot products of the drugs for the prevention and treatment of public health emergencies.
Chapter 2 Application Acceptance and On-site Inspection
Article 5 Where the special review and approval procedure for drug registration is initiated, the State Food and Drug Administration is responsible for the acceptance of registration applications for drugs for public health emergencies.
Where a drug or a preventive biological product for public health emergencies has not been marketed in China, the applicant shall, before submission of the registration application, provide the State Food and Drug Administration with relevant research and development information.
Article 6 The applicant shall submit a registration application with relevant technical dossier to the State Food and Drug Administration according to the relevant provisions and requirements on administration of drug registration.
The registration application for drug for public health emergencies may be submitted in electronic form.
Article 7 Before submitting an application for registration, the applicant may provide a feasibility assessment application with general information and relevant explanations. The State Food and Drug Administration shall only comment on the scientific rationality and feasibility of the drug project, and respond within 24 hours.
The response to a feasibility assessment application shall be neither deemed as the review and approval opinion nor legally binding on the review and approval result of a registration application.
Article 8 The State Food and Drug Administration shall organize an expert group to evaluate and review the registration application for drug for the prevention and treatment of public health emergencies, make a decision within 24 hours on whether or not to accept the application, and notify the applicant.
Article 9 Where a registration application is accepted, the State Food and Drug Administration shall organize technical review of submitted dossier within 24 hours and at the same time notify the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the applicant is located to conduct an on-site inspection on drug research and development conditions, and organize sampling and testing of pilot products.
The (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall, within five days, submit the on-site inspection result and relevant opinion to the State Food and Drug Administration.
Article 10 The (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall organize staff from the departments of drug registration, drug safety and inspection, etc. to participate in the on-site inspection.
The National Institute for the Control of Pharmaceutical and Biological Products shall be notified to send staff to participate in the on-site inspection and sampling of preventive biological products.
Article 11 For drugs that have existing national standards for the prevention and treatment of public health emergencies, the State Food and Drug Administration may directly review and approve the drug in accordance with the relevant provisions in Chapter 6 of the Procedure when it deems there is no need for a clinical trial in accordance with law.
Article 12 With respect to the registration application for a specific vaccine, where only the original virus strain used in the manufacturing is changed while the manufacturing processes or quality specifications are maintained, the State Food and Drug Administration shall make a decision on whether or not to grant the approval within three days after verifying the changed strain used in the manufacturing.
Chapter 3 Testing for Registration
Article 13 After receiving the samples taken by the (food and) drug regulatory department of a province, autonomous region, or municipality directly under the Central Government, the drug testing institution shall immediately organize verification of specifications and laboratory testing on the samples.
The drug testing institution shall complete the testing within the time frame for the drug being applied.
Article 14 For a drug applied first time for marketing, the State Food and Drug Administration may, when necessary, make early involvement by appointing the National Institute for the Control of Pharmaceutical and Biological Products to communicate with the applicant prior to testing for registration so as to timely resolve technical problems which may arise in the process of quality specifications verification and laboratory testing.
With respect to preventive biological products used to prevent and control the epidemic of serious infectious diseases, the State Food and Drug Administration may, depending on the situation, allow the testing for registration and the manufacturer’s self-testing to be performed in parallel.
Article 15 After completion of the specifications verification and laboratory testing on a drug, the drug testing institution shall, within two days, issue its verification opinion and submit it along with the drug test report to the State Food and Drug Administration.
Chapter 4 Technical Review
Article 16 The State Food and Drug Administration shall, within 15 days after acceptance of the registration application for drug for the prevention and treatment in public health emergencies, complete the first round of technical review.
Article 17 Where the State Food and Drug Administration considers that additional data are needed, it shall immediately inform the applicant of the content and timeline.
Where the applicant submits the supplementary data within the specified timeline, the State Food and Drug Administration shall complete the technical review within three days, or, depending on the situations, organize another review meeting within five days, and then complete the review report within two days.
Chapter 5 Clinical Trial
Article 18 Where the technical review is completed, the State Food and Drug Administration shall, within three days, complete the administrative examination, make a decision and inform the applicant.
Where the State Food and Drug Administration decides to approve a clinical trial, it shall issue a Drug Clinical Trial Approval. Where it decides not to approve, it shall issue a Disapproval Notice with reasons.
Article 19 Where an applicant obtains a clinical trial approval, it shall conduct the trial strictly following the relevant requirements in the approval document, and comply with the Good Clinical Practice.
Article 20 Drug clinical trials shall be conducted in institutions legally certified for drug clinical trials. If a clinical trial has to be conducted by an institution not yet certified, a special approval by the State Food and Drug Administration should be obtained.
The application for a clinical trial conducted by an institution not yet certified for drug clinical trials may be submitted along with the application for drug registration.
Article 21 The investigator responsible for a drug clinical trial shall, in accordance with the relevant provisions, timely report adverse events occurred in the process of the clinical trial to the State Food and Drug Administration. If no adverse event occurs, the investigator shall collect relevant information and report to the State Food and Drug Administration monthly.
Article 22 The State Food and Drug Administration shall, in accordance with law, supervise and inspect the clinical trials of drugs for public health emergencies.
Chapter 6 Review, Approval and Monitoring of Drug Production
Article 23 The applicant shall, after completion of the drug clinical trials, submit the relevant data to the State Food and Drug Administration in accordance with the Provisions for Drug Registration.
Article 24 The State Food and Drug Administration shall, within 24 hours after receiving data submitted by the applicant, organize technical review, and at the same time notify the (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the applicant is located to conduct the on-site inspection on the drug manufacturing conditions, and organize the sampling and testing of pilot products.
The (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall, within five days, submit the result and opinion of the on-site inspection to the State Food and Drug Administration.
Article 25 Any newly-established drug manufacturer or manufacturer with newly-built manufacturing workshops or newly-added dosage forms for production may apply to the State Food and Drug Administration for a certificate of the Good Manufacturing Practice along with the application for drug registration. The State Food and Drug Administration shall, when conducting the drug registration review, immediately carry out an inspection on the Good Manufacturing Practice certification.
Article 26 The drug testing institution shall, after receiving the samples of three batches taken by the (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, immediately arrange the testing.
Upon completion of testing, the drug testing institution shall, within two days, complete the test report and submit it to the State Food and Drug Administration.
Article 27 The State Food and Drug Administration shall carry out technical review in accordance with Chapter 4 of the Procedure, and shall, within three days after the completion of the technical review, complete the administrative examination, make a decision and inform the applicant.
Where the State Food and Drug Administration decides to approve the drug, it shall issue the Letter of Approval for Drug Registration, and may grant an approval number for the drug at the same time if the applicant has appropriate manufacturing conditions; if it decides to disapprove the manufacturing, it shall issue a Disapproval Notice with reasons.
Article 28 Where a drug manufacturer or distributor, or a medical and health institution finds any new or serious adverse drug reaction or cluster adverse reaction relating to a specially approved drug for public health emergencies, it shall immediately report the case to the local (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, the health administrative department at the provincial level and the professional institution for adverse drug reactions monitoring.
The professional institution for adverse drug reactions monitoring shall regard drugs specially approved for public health emergencies as critically monitored products, analyze the collected case reports in accordance with the relevant provisions and timely report to the (food and) drug regulatory department of the province, autonomous region, or municipality directly under the Central Government and the State Food and Drug Administration.
The State Food and Drug Administration shall reinforce the reevaluation of approved drugs for public health emergencies after they are marketed.
Chapter 7 Supplementary Provisions
Article 29 The measures for special review and approval of the medical devices for public health emergencies shall be separately formulated by the State Food and Drug Administration with reference to the relevant provisions of the Procedure.
Article 30 The Procedure shall go into effect as of the date of promulgation.
